ABSTRACT
In this chapter, the authors describe ours rationale and approach for treating low-density lipoprotein (LDL)-C in atherosclerotic cardiovascular disease (ASCVD) patients. High-intensity statin treatment is the cornerstone of secondary prevention and LDL- cholesterol management in patients with ASCVD. Non-statin lipid lowering drugs should be considered in patients intolerant of statins or in whom the LDL-C levels are not sufficiently low. The American College of Cardiology/American Heart Association 2013 guidelines recommend high-intensity statin treatment for all patients with ASCVD and moderate intensity statin treatment for those not suitable for high-intensity treatment. High-intensity statin treatment is the cornerstone of secondary prevention and LDL-C management in patients with ASCVD. The proprotein convertase subtilisin kexin type 9 inhibitors are our go-to drugs in patients intolerant of statins or in whom other lipid-lowering agents cannot reduce their LDL-C levels to a sufficiently low level.
